Seres Therapeutics, Inc. Insider Trading for June 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Seres Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Seres Therapeutics, Inc. for June 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Option Exercise | M | 7.79 | 4,533 | 35,312 | 233,454 | |
| Jun 30 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Sell | S | 29.54 | 4,533 | 133,905 | 0 | 4.5 K to 0 (-100.00 %) |
| Jun 30 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Buy | M | 7.79 | 4,533 | 35,312 | 4,533 | 0 to 4.5 K |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Sell | S | 27.23 | 9,390 | 255,690 | 32,655 | 42 K to 32.7 K (-22.33 %) |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Option Exercise | M | 7.79 | 1,667 | 12,986 | 237,987 | |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Option Exercise | M | 7.79 | 3,334 | 25,972 | 239,654 | |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Sell | S | 28.85 | 1,667 | 48,093 | 0 | 1.7 K to 0 (-100.00 %) |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Buy | M | 7.79 | 1,667 | 12,986 | 1,667 | 0 to 1.7 K |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Sell | S | 28.00 | 3,334 | 93,352 | 0 | 3.3 K to 0 (-100.00 %) |
| Jun 29 2016 | MCRB | Seres Therapeutics ... | Shaff Eric D. | CFO and EVP | Buy | M | 7.79 | 3,334 | 25,972 | 3,334 | 0 to 3.3 K |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 74,049 | 52,575 | 1,217,286 | |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 33.22 | 20,307 | 674,639 | 183,692 | 204 K to 183.7 K (-9.95 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 32.34 | 47,159 | 1,525,122 | 203,999 | 251.2 K to 204 K (-18.78 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 31.62 | 6,583 | 208,154 | 251,158 | 257.7 K to 251.2 K (-2.55 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 74,049 | 52,575 | 257,741 | 183.7 K to 257.7 K (+40.31 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | COOK DAVID N | Chief Scientific Of ... | Sell | S | 31.00 | 8,000 | 248,000 | 136,673 | 144.7 K to 136.7 K (-5.53 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | DesRosier Thomas | See Remarks | Option Exercise | A | 30.90 | 100,000 | 3,090,000 | 100,000 | |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | COOK DAVID N | Chief Scientific Of ... | Sell | S | 29.43 | 16,000 | 470,880 | 144,673 | 160.7 K to 144.7 K (-9.96 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 70,951 | 50,375 | 1,291,335 | |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.65 | 52,441 | 1,607,317 | 183,692 | 236.1 K to 183.7 K (-22.21 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.12 | 18,510 | 557,521 | 236,133 | 254.6 K to 236.1 K (-7.27 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 70,951 | 50,375 | 254,643 | 183.7 K to 254.6 K (+38.62 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Sell | S | 30.57 | 650 | 19,871 | 42,045 | 42.7 K to 42 K (-1.52 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Aunins John G. | Chief Technology Of ... | Sell | S | 30.02 | 13,365 | 401,217 | 42,695 | 56.1 K to 42.7 K (-23.84 %) |